# EDGAR Filing Document

**Accession Number:** 0001685428
**File Stem:** 0000950170-23-003222
**Filing Date:** 2023-2
**Character Count:** 5113
**Document Hash:** 2093222dc4191f7149c58c9ca3e85355
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-003222.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0000950170-23-003222

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230217

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LumiraDx Ltd
- **CENTRAL INDEX KEY:** 0001685428
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40852
- **FILM NUMBER:** 23643096

**BUSINESS ADDRESS:**
- **STREET 1:** 3 MORE LONDON RIVERSIDE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SE1 2AQ
- **BUSINESS PHONE:** 011 44 1786 430411

**MAIL ADDRESS:**
- **STREET 1:** 3 MORE LONDON RIVERSIDE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SE1 2AQ

**<br>UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549<br>FORM 6-K<br>REPORT OF FOREIGN PRIVATE ISSUER**

 **PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934<br>For the month of February 2023.<br>Commission File Number: 001-40852<br>LUMIRADX LIMITED**

**(Translation of registrant's name into English)<br>LumiraDx Limited<br>c/o Ocorian Trust (Cayman) Limited<br>PO Box 1350, Windward 3, Regatta Office Park<br>Grand Cayman KY1-1108**

**Cayman Islands**

**(354) 640-0540<br>(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

------

**EXPLANATORY NOTE**

On February 17, 2023, LumiraDx Limited (the "Company") issued a press release announcing that it has regained compliance with the continued listing requirements of the Nasdaq Global Market. A copy of this press release is furnished as Exhibit 99.1 herewith.

This report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the Company's registration statements on Form S-8 (File No: 333-259874 and File No. 333-264611), and on Form F-3 (File No: 333-264609), and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently furnished.

**EXHIBIT INDEX**

<u>Exhibit No.</u> <u>Description</u> <br> 99.1 [<u>Press release issued by LumiraDx Limited on February 17, 2023.</u>](lmdx-ex99_1.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **LUMIRADX LIMITED** | **LUMIRADX LIMITED** |
| Date: February 17, 2023 |  |  |
|  | By: | /s/ Dorian LeBlanc |
|  | Name: | Dorian LeBlanc |
|  | Title: | Chief Financial Officer |

---

------

## Ex-99

**Exhibit 99.1**

**LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements**

LONDON, February 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the "Company") today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

On January 27, 2023, Nasdaq notified the Company that its common shares had failed to maintain a minimum bid price of US$1.00 over the previous 30 consecutive trading days as required by the Listing Rules of The Nasdaq Stock Market. On February 17, 2023, Nasdaq notified the Company that for 11 consecutive business days, from February 2 to February 16, 2023, the closing bid price of the Company's common shares has been above US$1.00 per share. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) and Nasdaq has deemed this matter closed.

**About LumiraDx**

LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.

The Company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The Company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.

Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease. More information on LumiraDx is available at www.lumiradx.com.

------